MediciNova, Inc. (MNOV)

[microcapbiotech]

like I said... and it's going to go much higher.

[microcapbiotech]

Like a bird tweeting, cheap, cheap, cheap.
and then it flies, up, up, up.

[microcapbiotech]

three words, BUY NOW HOLD

[Minding]

MediciNova Announces Positive Top-Line Results from the Clinical Trial of MN-166 (ibudilast) in ALS (https://finance.yahoo.com/m/e3f98ddc-820c-3c3a-8485-7f469aaf4c3a/medicinova-stock-up-more-than.html)

I do love MNOV. Because the price jumped over $10 after hours (before falling back)? Nope. It's progress in ALS research. There's no finer way to invest.

Kind regards,
Minding

[stocktrademan]

MNOV bullish 6.54



normal chart


log chart

[someconcerns]

Thank you George.

[Minding]

Two things of interest if you follow this link: http://www.wallstreet.org/eps-expected-to-decrease-for-medicinova-inc-mnov/

First is analyst expectations for the next earnings release.

Second is the date of the next earnings release. I have found no press release from the company, but WallStreet.org says it's tomorrow, 4 February 2016.

Kind regards,
Minding

[stocktrademan]

$MNOV recent news/filings

bullish 3.532
inverted head and shoulders
moving average breakout

## source: finance.yahoo.com

Mon, 14 Dec 2015 08:59:00 GMT ~ 3:59 am MediciNova reports positive interim safety and clinical outcomes data from clinical trial of MN-166


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#mnov
*********************************************************

Sun, 13 Dec 2015 23:10:08 GMT ~ MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 26th International Symposium on ALS/MND in Orlando, FL

[at noodls] - , (GLOBE NEWSWIRE) -- , a biopharmaceutical company traded on the (NASDAQ:MNOV) and the JASDAQ Market of the (Code Number:4875), announced that principal investigator Dr. , Director, Neuromuscular/ALS-MDA ...

read full: http://www.noodls.com/view/058AA174BC313F7BD0D383FC78954FB6C16B8524
*********************************************************

Sun, 13 Dec 2015 23:00:00 GMT ~ MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 26th International Symposium on ALS/MND in Orlando, FL

[GlobeNewswire] - LA JOLLA, Calif., Dec. 13, 2015-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that principal investigator ...

read full: http://finance.yahoo.com/news/medicinova-announces-positive-interim-safety-230000214.html
*********************************************************

Wed, 09 Dec 2015 22:44:03 GMT ~ MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting

[at noodls] - MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting...

read full: http://www.noodls.com/view/6DB43E3D7B5CD8C01DCA3964BF96FB2673C95EFF
*********************************************************

Wed, 09 Dec 2015 22:30:00 GMT ~ MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting

[GlobeNewswire] - LA JOLLA, Calif., Dec. 09, 2015-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that Dr. Daniel Roche today ...

read full: http://finance.yahoo.com/news/medicinova-announces-positive-findings-clinical-223000485.html
*********************************************************

$MNOV charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$MNOV company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/MNOV/company-info
Ticker: $MNOV
OTC Market Place: Not Available
CIK code: 0001226616
Company name: Medicinova, Inc.
Incorporated In: DE, USA

Business Description:

$MNOV share structure

## source: otcmarkets.com

Market Value: $104,248,603 a/o Dec 11, 2015
Shares Outstanding: 29,956,495 a/o Oct 23, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001

$MNOV extra dd links

Company name: Medicinova, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=MNOV+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=MNOV+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=MNOV+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/MNOV/news - http://finance.yahoo.com/q/h?s=MNOV+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/MNOV/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/MNOV/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=MNOV+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/MNOV
DTCC (dtcc.com): http://search2.dtcc.com/?q=Medicinova%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Medicinova%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Medicinova%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/MNOV
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001226616&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/MNOV/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/MNOV/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=MNOV&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=MNOV
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/MNOV/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=MNOV+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=MNOV+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=MNOV
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=MNOV
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=MNOV+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/MNOV/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=MNOV+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/MNOV.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=MNOV
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/MNOV/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/MNOV
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/MNOV
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/MNOV:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=MNOV
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=MNOV



$MNOV DD Notes ~ http://www.ddnotesmaker.com/MNOV

[Minding]

S3 filed 12/1/2015: http://www.sec.gov/Archives/edgar/data/1226616/000119312515391096/d68859ds3.htm

2,000,000 Shares of Common Stock Offered by Selling Stockholders

Thanks to strange1 on ValueForum.

Kind regards,
Minding

[Minding]

A thought from my friend Carl:

MNOV is attempting to treat just about everything with its drugs. I have never seen any company of this size with so many irons in the fire. And they have been able to fund their trials with external sources of money.

MNOV's chart is improving. However it will take news that confirms that their drugs work in one of these research projects for a big move to take place. The market cap is about $97m so there is plenty of possible room to the upside if good news is revealed.

Kind regards,
Minding

-----------------

MediciNova initiates mid-stage study of MN-001 for elevated triglycerides in NASH patients

Nov 19 2015, 12:05 ET | By: Douglas W. House, SA News Editor Contact this editor with comments or a news tip
MediciNova (MNOV -1.9%) initiates a Phase 2a clinical trial assessing MN-001 (tipelukast) for the treatment of hypertriglyceridemia in NASH (nonalcoholic steatohepatitis) patients. The open-label, multicenter, proof-of-concept study will enroll ~20 participants. Eligible patients will have a confirmed diagnosis of NASH and serum triglyceride levels of at least 150 mg/dL (normal level is less than 150 mg/dL). Each subject will receive 250 mg of MN-001 once per day for four weeks followed by 250 mg twice per day for eight weeks.

MN-001 is under development for the treatment of NASH with fibrosis and ideopathic pulmonary fibrosis.

Tipelukast is a small molecule anti-fibrotic and anti-inflammatory compound that exerts its effects via several mechanisms, including leukotriene receptor antagonism and inhibiting enzymes known as phosphodiesterases as well as 5-lipoxygenase.

Previously: MediciNova's tipelukast Fast Track'd for ideopathic pulmonary fibrosis; shares up 17% premarket (Sept. 10)

Previously: MediciNova jumps on FDA OK of second Phase 2 protocol for MN-001 in NASH (July 27)



MediciNova Receives Notice of Allowance for New Patent Covering MN-221 (bedoradrine) for the Treatment of Irritable Bowel Syndrome in Japan

MNOV: Presentation on ALS Phase 2 Study in December?

FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of Idiopathic Pulmonary Fibrosis


MediciNova Announces First Advanced ALS Patient Using Non-Invasive Ventilation Support Enrolled in Phase 2 Clinical Trial of MN-166 (ibudilast)

MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence

MediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS

FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis

[someconcerns]

Just need to be patient. We will get news ... eventually.

[Minding]

One view, technical for the most part.

Kind regards,
Minding

---------------

From http://www.financialmagazin.com/what-will-happen-to-medicinova-inc-next-the-stock-just-reaches-52-week-low/

What Will Happen to MediciNova, Inc. Next? The Stock Just Reaches 52-Week Low

The stock of MediciNova, Inc. (MNOV) hit a new 52-week low and has $2.05 target or 28.00% below today’s $2.85 share price. The 8 months bearish chart indicates high risk for the $84.89 million company. The 1-year low was reported on Oct, 21 by Barchart.com. If the $2.05 price target is reached, the company will be worth $23.77M less.

The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock is up 2.15% or $0.06 after the news, hitting $2.85 per share. About 107,871 shares traded hands or 41.33% up from the average. MediciNova, Inc. (NASDAQ:MNOV) has declined 18.42% since March 18, 2015 and is downtrending. It has underperformed by 15.15% the S&P500.

Analysts await MediciNova, Inc. (NASDAQ:MNOV) to reports earnings on October, 29. After $-0.09 actual EPS reported by MediciNova, Inc. for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.

According to Zacks, “MEDICINOVA, INC. is a publicly-traded biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical need with a specific focus on the U.S. market. Through strategic alliances primarily with Japanese pharmaceutical companies, MediciNova holds rights to a diversified portfolio of clinical and preclinical product candidates, each of which MediciNova believes has a well-characterized and differentiated therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. MediciNova’s pipeline includes six clinical-stage compounds for the treatment of status asthmaticus, multiple sclerosis, asthma, interstitial cystitis, solid tumor cancers, Generalized Anxiety Disorder, preterm labor and urinary incontinence and two preclinical-stage compounds for the treatment of thrombotic disorders. MediciNova will seek to monetize its other product candidates at key value inflection points.”

The institutional sentiment increased to 1 in Q2 2015. Its up 0.55, from 0.45 in 2015Q1. The ratio increased, as 5 funds sold all MediciNova, Inc. shares owned while 4 reduced positions. 2 funds bought stakes while 7 increased positions. They now own 2.52 million shares or 0.18% more from 2.51 million shares in 2015Q1.

Essex Woodlands Health Ventures Inc. holds 0.83% of its portfolio in MediciNova, Inc. for 1.17 million shares. Bridgeway Capital Management Inc owns 66,592 shares or 0.01% of their US portfolio. Moreover, Bank Of America Corp De has 0% invested in the company for 3,020 shares. The United Kingdom-based Barclays Plc has invested 0% in the stock. Blackrock Fund Advisors, a California-based fund reported 60,997 shares.

[someconcerns]

Good, I'm glad you have enough patience for the MNOV volcano to build up steam. It will blow when it's ready.

[Ebuilder]

I am a bit surprised at the lack of traction in the stock. I thought for sure we'd at least climb above the last offering price. I'm looking for that climb to $8...I can wait.

Good luck!

[someconcerns]

This is true - that it has not yet added to SP - but I believe the value has increased incrementally. Study by study, funding by funding. We have a volcano building here.

[Minding]

While good news, it adds no value ... yet.

Tucked away.

Kind regards,
Minding

[someconcerns]

And there was another of those interesting surges in price following the news release by MNOV this morning ... followed by a drop back to nearly it's earlier level.

[Ebuilder]

I don't mind buying on the way up for legit prospects like MNOV. I'll get more when I can

[someconcerns]

We all wish we had bought more of our winners and less of our losers. ;-D

[Ebuilder]

Nice volume on fast track designation. Maybe we can start the move to $8. I do need to buy a few more, but all out of ammo at the current time.

[someconcerns]

You are equal to the task. MNOV and all our stocks will be just fine.

BTW, there are two Japanese underwriters, so these are being sold there too.

[Ebuilder]

Well, added again today...SOBs keep testing me....grrrr

[Ebuilder]

LoL......

[someconcerns]

No, just "stumpy."

[Ebuilder]

Call me toothless, would you like a straw, from catching all those knives

[someconcerns]

Cool. I have a firewall between my "investing" and "play" money and those funds I don't touch. All of the former are reserved for several of my falling knives.

[Ebuilder]

I was able to get some at $3.35. With all my stocks getting crushed, I'm about out of dry powder...which I can't believe I'm saying....sheesh. Anyway, if MNOV offers up at <$3.20 then I'll add again.

[someconcerns]

Happy to help. Just saw it in the Yahoo news feed. If they pull off the $3.50, it speaks volumes about the underlying demand. Still interested if it's also being sold in Japan and if insiders buy much.

Edit: http://finance.yahoo.com/news/medicinova-announces-pricing-underwritten-public-234313311.html

[Ebuilder]

Someone will be kicking themselves for th AH sells.. Heck, $3.50 is where it has been trading....lol. I'll be a buyer. Thanks for the update!

[someconcerns]

Offering is for 5m shares at $3.50 each.

[someconcerns]

And, as shown on IHub, it's back down. Probably just late recording of a trade.

[Ebuilder]

I see $3.18 on nasdaq.com.....we'll see

[Ebuilder]

There were a slew of small trades taking it down. I don't care, I'll buy in small bites.

[someconcerns]

I don't know if it means anything, at least any more than late recording of earlier trades, but it's interesting that the after-market trades are back up to where sp had been. We'll see after they announce pricing and quantity for the new shares.

Go MNOV!

[Ebuilder]

Ya buddy!

[someconcerns]

Great opptny to double your share count!

[Ebuilder]

I know I'll add at least three shares Been waiting for this op ... Glty

[someconcerns]

EB, Yes, possibly a pretty good sale to happen on MNOV shs. The ad should be in tomorrow's paper and we can all run and line up outside the doors of the store.

Probably, depending on how many shares, we'll be back to yesterday's level in a couple weeks or less. Will be interesting if the shares will be offered only here or also in Japan and which insiders may buy.

[Ebuilder]

On sale now I guess.....

[ClayTrader]

* * $MNOV Video Chart 07-27-15 * *

Link to Video - click here to watch the technical chart video

[someconcerns]

You too.

[Ebuilder]

Had I seen the run when it was over $5, I would have sold....maybe next time. But I did enjoy watching the action. I'd never seen one go straight up and come straight down like that. Usually there are a few V shapes in the graph...not today

Cheers to a good week!

[someconcerns]

EBuilder, As Minding reminded me, MNOV had a similar surge in April. Some people shorted during that and then covered. I sold a part of my long position at that time and repurchased a few days later at a lower level. This morning, my attention was divided and I left my shares alone.

[Ebuilder]

Hmm, can't say that I've ever seen a stock perform like this one did today. I guess it was such an obvious short, it never stood a chance.

[SavageInvestor]

Sell!! Broke yearly support at 4.45!!

[someconcerns]

Ah yes, good for the people who flipped MNOV this morning, then get back in later. Caught the handle (I think) of another of my falling knife stocks this am. At least so far.

[Minding]

Temporary pop as in April Steve.

=========

From http://finance.yahoo.com/news/medicinova-announces-fda-approval-second-120000112.html

MediciNova Announces FDA Approval of the Second Phase 2 Protocol for MN-001 in NASH Which Targets NASH Patients With Hypertriglyceridemia
MediciNova, Inc.
1 hour ago
GlobeNewswire
????
LA JOLLA, Calif., July 27, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number:4875), today announced that FDA (U.S. Food and Drug Administration) has approved a second protocol for a clinical trial evaluating MN-001 (tipelukast) for a NASH indication. This study targets NASH patients with hypertriglyceridemia to evaluate the ability of MN-001 to improve cardiovascular risk by assessing cholesterol-efflux capacity and serum triglyceride levels as well as reduction of percent fat in the liver, as assessed by MRI.

Yuichi Iwaki, MD, PhD, President and Chief Executive Officer of MediciNova, Inc., commented, "We are very pleased to have successfully completed the FDA review period and look forward to initiating patient enrollment shortly. The safety and efficacy data from this trial will be important to our overall development efforts targeting NASH and should be complementary to efforts underway. In previous clinical trials and preclinical studies, serum triglyceride levels were reduced in MN-001-treated groups. It is well known that NASH patients often have elevated serum lipid levels, one of the factors that contribute to cardiovascular disease. Recent studies have confirmed that cardiovascular disease is the single most important cause of mortality in this patient population. Importantly, MN-001's anti-fibrotic properties combined with its potential to reduce triglyceride levels in NASH patients offers a novel approach to the treatment of NASH."

About the Study Design

The Phase 2 trial is a single-center, proof-of-principle, open-label study designed to evaluate the efficacy, safety, and tolerability of MN-001 in subjects with nonalcoholic steatohepatitis (NASH) and hypertriglyceridemia. Eligible subjects will consist of males and females ranging in age from 21 to 65 years old, inclusive. To be eligible, subjects must have a histologically confirmed diagnosis of NASH within 6 months prior to the baseline visit and an elevated serum triglyceride (> 150 mg/dL) during the Screening Phase. Approximately twenty (20) qualifying subjects will be given MN-001 250 mg orally administered once a day for the first 4 weeks and will be given MN-001 250 mg twice a day for an additional 8 weeks. Overall, the study timeline consists of a Screening Phase (up to 4 months) followed by a Treatment Phase (12 weeks), and a Follow-up visit (within 1 week after the last dose).

The primary efficacy endpoints of the study are to evaluate the effect of MN-001 on 1) Triglyceride levels in NASH subjects with hypertriglyceridemia, and 2) Cholesterol Efflux Capacity in NASH subjects with hypertriglyceridemia. Secondary endpoints include safety and tolerability of MN-001, PK profile of MN-001/MN-002 (by-product of MN-001), effects of MN-001 on HDL-C, LDL-C, and total cholesterol level, and effects of MN-001/002 on liver enzymes and percent fat in liver assessed using MRI at Week 12.

Earlier this year, the FDA granted Fast-Track designation to MN-001 for the treatment of NASH with fibrosis. Fast Track is a process designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening diseases and demonstrate the potential to address unmet medical needs for such diseases. An important feature of the FDA's Fast Track program is that it emphasizes frequent communication between the FDA and the sponsor throughout the entire drug development and review process to improve the efficiency of product development. Accordingly, Fast Track status can potentially lead to a shortened timeline to ultimate drug approval.

Related Quotes
MNOV
4.89
+39.32%
MediciNova Inc.? Watchlist
4.89+1.38(39.32%)
NASDAQ9:57 AM EDT

MEDICINOVA INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits EDGAR Online 24 days ago
MEDICINOVA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online 1 mth 12 days ago
More
About Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis (NASH) is a condition in which there is fat in the liver along with inflammation and damage to liver cells. NASH is a common liver disease that resembles alcoholic liver disease but occurs in people who drink little or no alcohol. According to the U.S. National Digestive Diseases Information Clearinghouse (NDDIC), NASH prevalence in the U.S. is 2-5%, and an additional 10-20% of Americans have "fatty liver." The underlying cause of NASH is unclear, but it most often occurs in people who are middle-aged and overweight or obese. Many patients with NASH have elevated serum lipids, diabetes or pre-diabetes. Progression of NASH can lead to liver cirrhosis. Liver transplantation is the only treatment for advanced cirrhosis with liver failure. At this time, there is no treatment for NASH.

About MN-001

MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development and MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models.

Previously, MediciNova evaluated MN-001 for its potential clinical efficacy in asthma and had positive Phase 2 results. MN-001 has been exposed to more than 600 subjects and is considered generally safe and well-tolerated. Importantly, in these studies, reduction of serum triglyceride was observed for those treated with MN-001 in healthy volunteers and target populations.

About MediciNova

MediciNova, Inc. is a publicly-traded biopharmaceutical company founded upon acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs with a commercial focus on the U.S. market. MediciNova's current strategy is to focus on MN-166 (ibudilast) for neurological disorders such as progressive MS, ALS and substance dependence (e.g., methamphetamine dependence and opioid dependence), and MN-001 (tipelukast) for fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). MediciNova's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbations of asthma and MN-029 (denibulin) for solid tumor cancers. MediciNova is engaged in strategic partnering and other potential funding discussions to support further development of its programs. For more information on MediciNova, Inc., please visit www.medicinova.com.

Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-221, MN-001 and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," "considering," "planning" or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-221, MN-001 and MN-029, risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2014 and its subsequent periodic reports on Forms 10-Q and 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.

Contact:

[SidewaysTrader]

Looks like it's preping for a higher move.

[OB_WEALTH_INC]

MNOV @ $5.30 NOW..BANKING ON MY OWN ALERT

[someconcerns]

like the premarket price, FWIW, but looking for the cause.